MoodNCT06107075
Investigating the Effects of Dietary Phospholipids on Measures of Human Brain Health and Psychological Wellbeing
A study testing Active in people with Mood and Cognitive Change, run by Northumbria University at 1 site in United Kingdom.
Trial summary
The aim of this study is to investigate the effects of 6- and 12-week supplementation of a bioactive whey protein concentrate drink containing dairy phospholipids on cognitive function and mood in healthy young to middle aged adults. Read more about this study
- Who is it for?
- Ages 25 to 49 yearsHealthy volunteers can take part
- Conditions the study is for
- Mood, Cognitive Change, Well-Being, Psychological
- What is being tested?
- Active
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 119 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 2 Jan 2024to 25 Jul 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 49 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Participants must self-assess themselves as being in good health.
- Participants must be aged 25 to 49 years at the time of giving consent.
- Participant must be fluent in English and/or English is their first language
Who cannot join
- Have any pre-existing medical conditions/illness which will impact taking part in the study. There may be other, unforeseen exceptions and these will be considered on a case-by-case basis: i.e., participants may be allowed to progress to screening if they have a condition/illness which would not interact with the active treatments or impede performance. It is therefore worth discussing any medical conditions with the researcher prior to booking lab appointments
- Are currently taking any prescription medications (NOTE the explicit exceptions to this are contraceptive treatments for female participants, and those taking "as needed" in the treatment of asthma and/or hay fever. There may be other instances of medication use which, where no interaction with the active treatment is likely, and which would not be expected to have any impact on brain function, participants may be able to progress to screening
- Have high blood pressure (systolic over 159 mm Hg or diastolic over 99 mm Hg). NOTE: that we must measure this in the lab using our blood pressure monitors and can only use our measurements to assess eligibility rather than home or GP readings
- Have a Body Mass Index (BMI) outside of the range 18.5-35 kg/m2.
- Are pregnant, seeking to become pregnant or lactating.
- Have been diagnosed with a neurological condition, or assessed as having a learning/behavioural or neurodevelopmental difference (e.g. dyslexia, autism, ADHD.
Show all 30Show fewer
- Have a visual impairment that cannot be corrected with glasses or contact lenses (including colour-blindness)
- Smoke tobacco or vape nicotine or use nicotine replacement products (if you have recently quit smoking or using replacements you must have stopped using them altogether for a period of 3 months before participating in this study)
- Have excessive caffeine intake (>500 mg per day). Note: This will be calculated at screening but feel free to query this with the researcher prior to attendance
- Have relevant food allergies/ intolerances/ sensitivities
- Have taken antibiotics within the past 4 weeks.
- Have taken dietary supplements e.g., vitamins, omega 3 fish oils etc. in the last 4 weeks (Note: participation is possible following a 4 week supplement wash out prior to participating and for the duration of the study on the proviso that the supplements they are taking are out of choice and not medically prescribed or advised. Please discuss with the researcher if unsure. NOTE: we would never advise stopping supplements prescribed by your doctor e.g., iron, calcium etc., only those you use out of choice)
- Have any health condition that would prevent fulfilment of the study requirements (this includes non-diagnosed conditions for which no medication may be taken)
- Are unable to complete all of the study assessments (this will be assessed by the researcher at your training appointment, you must be able to reach minimum scores for each of the cognitive tasks to progress with the trial)
- Are currently participating in other clinical or nutrition intervention studies, or have in the past 4 weeks
- Have been diagnosed with/ undergoing treatment for alcohol or drug abuse in the last 12 months.
- Have been diagnosed with/ undergoing treatment for a psychiatric disorder in the last 12 months, including a medical diagnosis of anxiety or depression.
- Suffers from frequent migraines that require medication (more than or equal to 1 per month)
- Have any sleep disorders or take any sleep medications.
- Have any known active infections.
- Have, previously have had, or think you are at risk of having syphilis, hepatitis, the Human T - lymphotropic virus or the Human Immunodeficiency Virus (HIV)
- Have ever had breast cancer and/or a mastectomy.
- Have haemophilia or any similar clotting/blood disorder.
- Have had unprotected sexual intercourse with any person from an HIV high risk population.
- Have ever been involved in intravenous drug use.
- Does not have a bank account (required for payment)
- Are non-compliant with regards treatment consumption
- Follow an "extreme" or very "strict" diet i.e., Keto, very high protein, sugar free, raw paleo etc.
- Are planning a major lifestyle change regarding diet or exercise regime in the next 3 months.
- Have a current diagnosis of renal impairments or phenylketonuria
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Northumbria University - Brain Performance and Nutrition Research Centre
Newcastle upon Tyne
About this study
The aim of this study is to investigate the effects of 6- and 12-week supplementation of a bioactive whey protein concentrate drink containing dairy phospholipids on cognitive function and mood in healthy young to middle aged adults.
The proposed randomised, double blind, placebo-controlled, parallel groups design methodology will assess the cognitive, mood and lifestyle effects of 40g per day of bioactive whey protein concentrate powder mixed with water and matched placebo prior to (baseline) and after -6 and 12-week supplementation. The trial will utilise the COMPASS cognitive assessment system (Northumbria University) during the laboratory visits to measure performance on the cognitive tasks and a range of mood measures between visits examining general mood, stress, depression, anxiety, sleep quality, fatigue, and physical symptoms.
Read more
Additionally, dairy dietary habits will be recorded throughout to allow for any significant changes to diet to be assessed for the potential influence on the outcome variables.
Participants will be asked not to make any major changes to their diet or exercise regime for the duration of the trial. This will be checked by asking the participant if there has been any significant changes at each visit.
Blood samples will also be taken from a subset of participants who opt into this part of the trial to measure any changes to plasma phospholipid profiles.
220 participants will participate, aged 25-49, and self-report as in good health. Participants will be supplied with the treatment whilst visiting the research centre on testing days and will then consume treatment at home daily. Participants will record the time they take their treatment each day in a diary that will then be returned to the research team at the end of the study testing period.
Read the detailed description
The study will follow a randomised, placebo-controlled, double-blind, parallel groups design.
Participants will attend the research centre on four separate occasions, which will include a screening/training visit, pre intervention testing visit, a mid-point testing visit (at 6 weeks), and a completion of intervention testing visit (at 12 weeks). There will be 5 appointments in total including the online appointment to check for eligibility. The remote screening session will be completed via telephone call and will comprise briefing on the requirements for the study, answering any initial questions, obtaining of informed consent via completion of an online consent form, health screening, collection of demographic information, and completion of the Caffeine Consumption Questionnaire (CCQ).
The introductory/training visit to the laboratory will begin with physiological eligibility measures that cannot be completed remotely (e.g., blood pressure, height and weight, waist-to-hip ratio) followed by training on the cognitive and mood measures.
Opportunity sampling will be used to recruit participants. The study will include 220 healthy participants aged between 25-49 years, who will receive 12 weeks' worth of either 40g per day of bioactive whey protein concentrate powder containing dairy phospholipids (to be mixed with approx. 350ml water to form a drink), or similar amount per day of matched placebo powder. Participants will be randomly allocated to either the treatment or placebo group and neither the participant nor the researcher will know which group they have been allocated to. Full instructions of how and when to take treatment each day will be explained to the participants when treatment is provided at testing visit 1.
The day before each of the study testing days, participants will be sent a link to a set of questionnaires they must complete before attending the lab on the following day. The set includes questionnaires measuring perceived stress, sleep quality, levels of fatigue, physical symptoms, and general health and well-being. The questionnaires should take the participants approx. 45 minutes to complete on their computer, smartphone, or tablet at home.
On each of the three study testing days (Day 1, 42, and 84) participants will attend the research centre, having abstained from alcohol for 24 hours, and caffeine overnight, following a standardised breakfast of cereal and/or toast at home no later than 1 hour prior to arrival. Upon arrival to the research centre, participants continued eligibility will be checked before completing the 1 hour long computerised cognitive assessment using the Computerised mental performance assessment system (COMPASS). The cognitive assessment will employ a broad selection of tasks assessing performance within the "Attention", "Working Memory", "Episodic Memory", "learning" and "Executive Function" cognitive domains. The cognitive demand battery (CDB), which assess cognitive functioning and subjective mental fatigue during sustained performance of mentally demanding tasks, will also be incorporated. Upon completion of the computerised cognitive assessment, participants will complete the NASA task load index (NASA TLX) to measure perceived task mental demand.
Participants will additionally complete a treatment guess form at their final visit and will be fully debriefed.
Participants that opt into the blood sampling portion of this study will also attend the research centre on two separate additional occasions, the day (or two days) before the first and final testing visit, to have their blood taken. Participants will be required to attend the research centre fasted and therefore all blood draw appointments will be held in the morning. A venous blood sample will be taken by a trained phlebotomist. Samples will then be processed and stored at Northumbria University until time of analysis where they will be analysed for plasma phospholipid profiles. These additional blood visit will last approx. 15 minutes per visit.
- Conditions
- Mood, Cognitive Change, Well-Being, Psychological
- Being tested
- Active, Placebo
- Keywords
- Cognition, Mood, Well-being, Physical Health
- Medical subject headings
- Psychological Well-Being
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ActiveDietary supplement
Also called active treatment
40g bio-active whey protein concentrate powder containing phospholipids
PlaceboDietary supplement
Also called Placebo Treatment
around 40g pea protein powder not containing phospholipids
| Study group | Role | What they receive |
|---|---|---|
| Bioactive whey protein concentrate containing phospholipids | Experimental | Bioactive whey protein concentrate containing phospholipids 40g powder mixed with 350ml water consumed once daily for 12 weeks alongside their fattiest meal of the day. Receives: Dietary Supplement: Active |
| Placebo | Placebo comparator | Placebo powder matched for macronutrient and caloric content containing pea protein around 40g powder mixed with 350ml water consumed once daily for 12 weeks alongside their fattiest meal of the day. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cognitive function - Cognitive domain factor score
Effects of supplementation on the cognitive domain memory, measured using the following tasks through the Computerised Mental Performance Assessment System (COMPASS, Northumbria University) :Numeric Working Memory, immediate word recall, delayed word recall, delayed word recognition, and delayed picture recognition. Participants will receive scores of accuracies on all tasks, which will be in the form of the percentage of responses correct. Higher scores indicate better memory performance, lower scores indicate worse memory performance.
Measured: prior to (baseline) and following chronic dose of intervention at 6 weeks and 12 weeks.
Secondary outcomes (12)
Profile of Mood States (POMS)
65-item measure, summed to create measures of vigour-activity (range 0-32), tension-anxiety (range 0-36), fatigue-inertia (0-28), depression-dejection (0-60), confusion-bewilderment (0-28), and anger-hostility (0-48). Higher scores indicate higher current levels of each aspect of mood. Answers are rated using a 5-point scale between "not at all (0)" and "extremely (4)".
Measured: prior to (baseline) and following 6- and 12-week chronic intervention
Perceived Stress Scale (PSS)
10-item measure, summed to create a single value with higher scores indicating higher levels of stress. Scores can range from 0 to 40. Scores ranging from 0-13 would be considered low perceived stress, scores ranging from 14-26 would be considered moderate perceived stress, and scores ranging from 27-40 would be considered high perceived stress.
Measured: prior to (baseline) and following 6- and 12-week chronic intervention
Perceived Stress Reactivity Scale (PSRS)
23-item measure, summed to create measures of prolonged reactivity (scores from 0-8), reactivity to work overload (scores from 0-10), reactivity to social conflict (scores from 0-10), reactivity to failure (scores from 0-8), reactivity to social evaluation (scores from 0-10), and perceived stress reactivity total (scores from 0-46). Higher scores indicate higher perceived stress reactivity.
Measured: prior to (baseline) and following 6- and 12- week chronic intervention
The Cohen-Hoberman Inventory of Physical Symptoms (CHIPS)
33-item measure, summed to create a measure of number of health complaints in the previous 2 weeks. Answers are recorded using a 5-item Likert scale ranging from 0 (meaning they have not been bothered by this problem), to 4 (meaning the problem has been an extreme bother). All the scores across the 33 items will be summed together to create a total score. The score will range from 0 to 132 and will indicate how extensively a participant has been bothered by physical symptoms in the previous 2-week period (higher scores indicating more bothered by physical symptoms).
Measured: Prior to (baseline) and following 6- and 12- week chronic intervention
Subjective sleep via the Patient-Reported Outcome Measurement, Information System Sleep Disturbance Scale- shoer form (PROMIS-SD)
prior to (baseline) and following 6- and 12-week chronic intervention Description: 8-item measure, summed to create a single value with higher scores indicating higher levels of sleep disturbances. Responses are recorded using a 5-item Likert scale ranging from 1 (Not at all) to 5 (Very much). Total score will therefore range from 8 to 40.
Measured: prior to (baseline) and following 6- and 12-week chronic intervention
Depression, Anxiety and Stress Scale (DASS-21)
21 item measure, summed to create 3 component scores; depression, anxiety and stress. Responses recorded using a 4-item Liker scale (0-3). Raw score range rom 0-63 as an indication of overall distress (the higher the score the more general distress). Depression, anxiety, and stress scored between 0 and 21. The higher the score indicated higher levels of depression, anxiety and stress.
Measured: Prior to (baseline) and following 6- and 12-week chronic intervention
Fatigue Assessment Scale (FAS)
10-item measure, summed to create a measure of over perceived fatigue where less than 22 indicates "normal" levels of fatigue, 22-34 indicates mild-to-moderate fatigue and 35 or higher indicates severe fatigue. Total score ranges from 10 to 50.
Measured: prior to (baseline) and following 6- and 12- week chronic supplementation
Perceived task demand via the NASA Task Load Index (NASA TLX)
five 7-point scales summed to create a measure of perceived mental workload of the cognitive tasks. Higher scores indicating higher perceived task demand.
Measured: Following each of the cognitive assessments (3) at baseline, 6- weeks, and 12-week supplementation.
Cognitive function- individual cognitive task score
location learning task (accuracy), immediate word recall (accuracy), delayed word recall (accuracy) , delayed word recognition (accuracy and reaction time), delayed picture recognition (accuracy and reaction time), simple reaction time (reaction time), numeric working memory (accuracy and reaction time), Stroop (accuracy and reaction time), delayed location learning task (accuracy), and arrow flankers measured through the software Computerised Mental Performance Assessment System (COMPASS), Northumbria University. Scores for accuracy are the percentage of correct responses on that task. Reaction time is measures in milliseconds, and the lower the score the faster the response time.
Measured: prior to (baseline) and following 6- and 12- week chronic supplementation
Cognitive function- cognitively demanding tasks
cognitive function (scores based on number of answers correct within the time frame for serial subtractions, and accuracy of correct responses and reaction time measured in milliseconds for rapid visual information processing task) and mental fatigue (measured using a bespoke visual assessment scale) during extended performance of cognitively demanding tasks (cognitive demand battery, comprising serial 3s subtractions, serial 7s subtractions, rapid visual information processing task, and mental fatigue scales, repeated 3 times), measured though the software Computerised Mental Performance Assessment System (COMPASS), Northumbria University.
Measured: prior to (baseline) and following 6- and 12- week supplementation
Changes to blood plasma phospholipid profiles
Using venous blood samples to measure changes to plasma phospholipid profiles pre and post intervention.
Measured: prior to (baseline) and following 12-week chronic supplementation
Cognitive function - cognitive domain factor scores
Speed of attention (reaction time), accuracy of attention (accuracy), speed of memory (reaction time), accuracy of working memory (accuracy), accuracy of executive function (accuracy), learning (accuracy), delayed learning (accuracy) and accuracy of episodic memory (accuracy) measured by Computerised Mental Performance Assessment System (COMPASS, Northumbria University). Scores for accuracy are the percentage of correct responses on that task. Reaction time is measures in milliseconds, and the lower the score the faster the response time.
Measured: prior to (baseline) and following chronic dose of intervention at 6 weeks and 12 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Oct 2023
- Study start2 Jan 2024
- Primary completion25 Jul 2025
- Study completion25 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MoodStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomised, placebo-controlled, double-blind, parallel groups design
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 119 participants (actual)
Sponsor and investigators
- Lead sponsor
- Northumbria University
- Sponsor type
- University, hospital or other
- Collaborators
- Volac International Ltd
- Responsible party
- Principal investigator, Philippa Jackson, Northumbria University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06107075
- Sponsor's protocol ID
- 66CH1
- Status last verified
- Jun 2026
- First submitted
- 24 Oct 2023
- Last updated
- 25 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigating the Effects of Dietary Phospholipids on Measures of Human Brain Health and Psychological Wellbeing
- ClinicalTrials.gov ID
- NCT06107075
- Acronym / sponsor ID
- 66CH1
- Conditions
- Mood, Cognitive Change, Well-Being, Psychological
- Keywords
- Cognition, Mood, Well-being, Physical Health
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 119 participants (actual)
- Lead sponsor
- Northumbria UniversityUniversity, hospital or other
- Collaborators
- Volac International Ltd
- Study start
- 2 Jan 2024 (actual)
- Primary completion
- 25 Jul 2025 (actual)
- Study completion
- 25 Jul 2025 (actual)
- First posted
- 30 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to investigate the effects of 6- and 12-week supplementation of a bioactive whey protein concentrate drink containing dairy phospholipids on cognitive function and mood in healthy young to middle aged adults.
The proposed randomised, double blind, placebo-controlled, parallel groups design methodology will assess the cognitive, mood and lifestyle effects of 40g per day of bioactive whey protein concentrate powder mixed with water and matched placebo prior to (baseline) and after -6 and 12-week supplementation. The trial will utilise the COMPASS cognitive assessment system (Northumbria University) during the laboratory visits to measure performance on the cognitive tasks and a range of mood measures between visits examining general mood, stress, depression, anxiety, sleep quality, fatigue, and physical symptoms.
Additionally, dairy dietary habits will be recorded throughout to allow for any significant changes to diet to be assessed for the potential influence on the outcome variables.
Participants will be asked not to make any major changes to their diet or exercise regime for the duration of the trial. This will be checked by asking the participant if there has been any significant changes at each visit.
Blood samples will also be taken from a subset of participants who opt into this part of the trial to measure any changes to plasma phospholipid profiles.
220 participants will participate, aged 25-49, and self-report as in good health. Participants will be supplied with the treatment whilst visiting the research centre on testing days and will then consume treatment at home daily. Participants will record the time they take their treatment each day in a diary that will then be returned to the research team at the end of the study testing period.
Detailed description
The study will follow a randomised, placebo-controlled, double-blind, parallel groups design.
Participants will attend the research centre on four separate occasions, which will include a screening/training visit, pre intervention testing visit, a mid-point testing visit (at 6 weeks), and a completion of intervention testing visit (at 12 weeks). There will be 5 appointments in total including the online appointment to check for eligibility. The remote screening session will be completed via telephone call and will comprise briefing on the requirements for the study, answering any initial questions, obtaining of informed consent via completion of an online consent form, health screening, collection of demographic information, and completion of the Caffeine Consumption Questionnaire (CCQ).
The introductory/training visit to the laboratory will begin with physiological eligibility measures that cannot be completed remotely (e.g., blood pressure, height and weight, waist-to-hip ratio) followed by training on the cognitive and mood measures.
Opportunity sampling will be used to recruit participants. The study will include 220 healthy participants aged between 25-49 years, who will receive 12 weeks' worth of either 40g per day of bioactive whey protein concentrate powder containing dairy phospholipids (to be mixed with approx. 350ml water to form a drink), or similar amount per day of matched placebo powder. Participants will be randomly allocated to either the treatment or placebo group and neither the participant nor the researcher will know which group they have been allocated to. Full instructions of how and when to take treatment each day will be explained to the participants when treatment is provided at testing visit 1.
The day before each of the study testing days, participants will be sent a link to a set of questionnaires they must complete before attending the lab on the following day. The set includes questionnaires measuring perceived stress, sleep quality, levels of fatigue, physical symptoms, and general health and well-being. The questionnaires should take the participants approx. 45 minutes to complete on their computer, smartphone, or tablet at home.
On each of the three study testing days (Day 1, 42, and 84) participants will attend the research centre, having abstained from alcohol for 24 hours, and caffeine overnight, following a standardised breakfast of cereal and/or toast at home no later than 1 hour prior to arrival. Upon arrival to the research centre, participants continued eligibility will be checked before completing the 1 hour long computerised cognitive assessment using the Computerised mental performance assessment system (COMPASS). The cognitive assessment will employ a broad selection of tasks assessing performance within the "Attention", "Working Memory", "Episodic Memory", "learning" and "Executive Function" cognitive domains. The cognitive demand battery (CDB), which assess cognitive functioning and subjective mental fatigue during sustained performance of mentally demanding tasks, will also be incorporated. Upon completion of the computerised cognitive assessment, participants will complete the NASA task load index (NASA TLX) to measure perceived task mental demand.
Participants will additionally complete a treatment guess form at their final visit and will be fully debriefed.
Participants that opt into the blood sampling portion of this study will also attend the research centre on two separate additional occasions, the day (or two days) before the first and final testing visit, to have their blood taken. Participants will be required to attend the research centre fasted and therefore all blood draw appointments will be held in the morning. A venous blood sample will be taken by a trained phlebotomist. Samples will then be processed and stored at Northumbria University until time of analysis where they will be analysed for plasma phospholipid profiles. These additional blood visit will last approx. 15 minutes per visit.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Randomised, placebo-controlled, double-blind, parallel groups design
| Arm | Type | Receives |
|---|---|---|
| Bioactive whey protein concentrate containing phospholipids | Experimental | Dietary Supplement: ActiveBioactive whey protein concentrate containing phospholipids 40g powder mixed with 350ml water consumed once daily for 12 weeks alongside their fattiest meal of the day. |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboPlacebo powder matched for macronutrient and caloric content containing pea protein around 40g powder mixed with 350ml water consumed once daily for 12 weeks alongside their fattiest meal of the day. |
Who may qualify
- Ages
- 25 to 49 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Participants must self-assess themselves as being in good health.
- Participants must be aged 25 to 49 years at the time of giving consent.
- Participant must be fluent in English and/or English is their first language
Key exclusion criteria (30 listed)
- Have any pre-existing medical conditions/illness which will impact taking part in the study. There may be other, unforeseen exceptions and these will be considered on a case-by-case basis: i.e., participants may be allowed to progress to screening if they have a condition/illness which would not interact with the active treatments or impede performance. It is therefore worth discussing any medical conditions with the researcher prior to booking lab appointments
- Are currently taking any prescription medications (NOTE the explicit exceptions to this are contraceptive treatments for female participants, and those taking "as needed" in the treatment of asthma and/or hay fever. There may be other instances of medication use which, where no interaction with the active treatment is likely, and which would not be expected to have any impact on brain function, participants may be able to progress to screening
- Have high blood pressure (systolic over 159 mm Hg or diastolic over 99 mm Hg). NOTE: that we must measure this in the lab using our blood pressure monitors and can only use our measurements to assess eligibility rather than home or GP readings
- Have a Body Mass Index (BMI) outside of the range 18.5-35 kg/m2.
- Are pregnant, seeking to become pregnant or lactating.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ActiveAlso: active treatment40g bio-active whey protein concentrate powder containing phospholipids | Dietary supplement | Bioactive whey protein concentrate containing phospholipids |
| PlaceboAlso: Placebo Treatmentaround 40g pea protein powder not containing phospholipids | Dietary supplement | Placebo |
Primary outcome
Cognitive function - Cognitive domain factor score
Time frame: prior to (baseline) and following chronic dose of intervention at 6 weeks and 12 weeks.
Effects of supplementation on the cognitive domain memory, measured using the following tasks through the Computerised Mental Performance Assessment System (COMPASS, Northumbria University) :Numeric Working Memory, immediate word recall, delayed word recall, delayed word recognition, and delayed picture recognition. Participants will receive scores of accuracies on all tasks, which will be in the form of the percentage of responses correct. Higher scores indicate better memory performance, lower scores indicate worse memory performance.
12 secondary outcomes
Profile of Mood States (POMS)
Time frame: prior to (baseline) and following 6- and 12-week chronic intervention
Perceived Stress Scale (PSS)
Time frame: prior to (baseline) and following 6- and 12-week chronic intervention
Perceived Stress Reactivity Scale (PSRS)
Time frame: prior to (baseline) and following 6- and 12- week chronic intervention
The Cohen-Hoberman Inventory of Physical Symptoms (CHIPS)
Time frame: Prior to (baseline) and following 6- and 12- week chronic intervention
Subjective sleep via the Patient-Reported Outcome Measurement, Information System Sleep Disturbance Scale- shoer form (PROMIS-SD)
Time frame: prior to (baseline) and following 6- and 12-week chronic intervention
Depression, Anxiety and Stress Scale (DASS-21)
Time frame: Prior to (baseline) and following 6- and 12-week chronic intervention
Fatigue Assessment Scale (FAS)
Time frame: prior to (baseline) and following 6- and 12- week chronic supplementation
Perceived task demand via the NASA Task Load Index (NASA TLX)
Time frame: Following each of the cognitive assessments (3) at baseline, 6- weeks, and 12-week supplementation.
Cognitive function- individual cognitive task score
Time frame: prior to (baseline) and following 6- and 12- week chronic supplementation
Cognitive function- cognitively demanding tasks
Time frame: prior to (baseline) and following 6- and 12- week supplementation
Changes to blood plasma phospholipid profiles
Time frame: prior to (baseline) and following 12-week chronic supplementation
Cognitive function - cognitive domain factor scores
Time frame: prior to (baseline) and following chronic dose of intervention at 6 weeks and 12 weeks.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Mood
Recruiting
Unified Protocol in Penitentiary Facilities
Depression Disorders, Anxiety
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
RecruitingPhase 4
Biomarker-Guided Antidepressant Selection
Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD)
Recruiting
Targeting Network Dysfunction in Apathy of Late-life Depression Using Digital Therapeutics
Major Depressive Disorder, Apathy
RecruitingObservational study
Psychotherapy for Irritability in Youth: Comparing Active Treatment to Nonactive Psychoeducation Supportive Psychotherapy
Irritability, Disruptive Mood Dysregulation Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Active in people with Mood and Cognitive Change, run by Northumbria University at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cognitive function - Cognitive domain factor score (time frame: prior to (baseline) and following chronic dose of intervention at 6 weeks and 12 weeks.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2026.